Investigation of resveratrol as a xanthine oxidase inhibitor: Mechanistic insights and therapeutic implications for gout and hyperuricemia

被引:0
|
作者
Chen, Jianmin [1 ,2 ,3 ]
Chen, Juan [1 ]
Feng, Baozhu [1 ]
Ning, Meilian [1 ]
Wu, Wanhui [1 ]
Zou, Shiqi [1 ]
机构
[1] Putian Univ, Sch Pharm, Putian 351100, Fujian, Peoples R China
[2] Putian Univ, Fujian Prov Univ, Key Lab Pharmaceut Anal, Putian, Fujian, Peoples R China
[3] Putian Univ, Fujian Prov Univ, Lab Med, Putian, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
allopurinol; hyperuricemia; resveratrol; uric acid; xanthine oxidase; URIC-ACID; IN-VITRO; OXIDOREDUCTASE; TOPIROXOSTAT; TYROSINASE;
D O I
10.1002/bab.2690
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gout predominantly stems from hyperuricemia, precipitating the accumulation of urate crystals and consequent joint inflammation, swelling, and pain, thereby compromising the quality of life and presenting a formidable medical dilemma. Although conventional treatments like allopurinol and febuxostat target uric acid reduction via xanthine oxidase (XO) inhibition, they often entail adverse effects, prompting the exploration of safer alternatives. Resveratrol, a polyphenolic compound abundant in fruits and vegetables, has emerged as a potential XO inhibitor. However, its precise inhibitory mechanisms remain poorly understood. This study aims to comprehensively investigate resveratrol's XO inhibition through mechanistic insights, molecular docking simulations, animal model experiments, and biochemical analysis, contributing valuable insights to the development of novel therapeutics for hyperuricemia and gout.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Hiroshi Matsuo
    Eiji Ishikawa
    Hirofumi Machida
    Yasuhide Mizutani
    Akiko Tanoue
    Takahiro Ohnishi
    Tomohiro Murata
    Shinya Okamoto
    Toru Ogura
    Yuki Nishimura
    Hiroo Ito
    Masashi Yasutomi
    Kan Katayama
    Shinsuke Nomura
    Masaaki Ito
    Clinical and Experimental Nephrology, 2020, 24 : 307 - 313
  • [22] HYPERURICEMIA IN NEOPLASTIC DISEASE IN CHILDREN - PREVENTION WITH ALLOPURINOL A XANTHINE OXIDASE INHIBITOR
    KRAKOFF, IH
    MURPHY, ML
    PEDIATRICS, 1968, 41 (1P1) : 52 - &
  • [23] TMX-67, a novel xanthine oxidase/xanthine dehydrogenase (XOD) inhibitor, shows strong uric acid lowering action in patients with hyperuricemia and gout.
    Ishiwata, Y
    Kubo, J
    Komoriya, K
    Yamanaka, H
    Kamatani, N
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S129 - S129
  • [24] EFFECTS OF XANTHINE OXIDASE INHIBITOR ON CLINICAL MANIFESTATIONS + PURINE METABOLISM IN GOUT
    RUNDLES, RW
    SILBERMAN, HR
    ELION, GB
    HITCHINGS, GH
    ANNALS OF INTERNAL MEDICINE, 1964, 60 (04) : 717 - +
  • [25] Identification and mechanistic study of piceatannol as a natural xanthine oxidase inhibitor
    Yan, Xinxu
    Feng, Baolong
    Song, Hongjie
    Wang, Lili
    Wang, Yehui
    Sun, Yulin
    Cai, Xiaoshuang
    Rong, Yating
    Wang, Xibo
    Wang, Yutang
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 293
  • [26] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015)
    Ojha, Ritu
    Singh, Jagjeet
    Ojha, Anu
    Singh, Harbinder
    Sharma, Sahil
    Nepali, Kunal
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2017, 27 (03) : 311 - 345
  • [27] Long-term safety and efficacy of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in subjects with hyperuricemia and gout
    Schumacher, HR
    Wortmann, R
    Becker, M
    MacDonald, P
    Palo, W
    Streit, J
    Lademacher, C
    Joseph-Ridge, N
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 498 - 498
  • [28] Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies
    Saag, Kenneth G.
    Dalbeth, Nicola
    Hsu, Chi-yuan
    Kuo, Chang-Fu
    Nuki, George
    Perez-Ruiz, Fernando
    White, William B.
    Hariri, Ali
    Lee, Yunjung
    Jang, Younghwan
    Han, Song
    Choi, Hyon K.
    CONTEMPORARY CLINICAL TRIALS, 2025, 151
  • [29] Xanthine Oxidase Inhibitor Treatment and the Risk of Type 2 Diabetes in Patients with Gout
    Desai, Rishi J.
    Solomon, Daniel H.
    Franklin, Jessica M.
    Spoendlin, Julia
    Danaei, Goodarz
    Kim, Seoyoung
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 248 - 248
  • [30] Characterization of an Anti-gout Xanthine Oxidase Inhibitor from Pleurotus ostreatus
    Jang, In-Taek
    Hyun, Se-Hee
    Shin, Ja-Won
    Lee, Yun-Hae
    Ji, Jeong-Hyun
    Lee, Jong-Soo
    MYCOBIOLOGY, 2014, 42 (03) : 296 - 300